Lung Cancer Patients Successfully Treated in Clinical Trials by Israeli Bio-Medical Start-Up IceCure
Israeli bio-medical company IceCure Ltd. said two lung cancer patients in Japan were successfully treated with its IceSense3 cryotherapy system, as part of a clinical trial funded by Kameda Medical Center, in Japan.
IceCure’s lead product, IceSense3, freezes and destroys benign breast tumors in women via a process called cryoablation. It received 510(k) marketing clearance from the U.S. Food and Drug Administration in late-2010.
MedCityNews reported that IceCure says its method of treating fibroadenomas, noncancerous breast tumors, offers a number of advantages over the conventional way of treating them, typically a lumpectomy. Because cryoablation is a minimally invasive procedure, the IceSense creates less scarring and can be done quickly at a doctor’s office using only a local anesthetic, according to the company.
IceCure’s system is also undergoing clinical trials to treat breast cancer tumors in the U.S., Israel’s Globes business daily reported on Tuesday.
“We’re pleased at the success in destroying lung cancer tumors because use of our cryoablation platform could open to us a potential market of hundreds of thousands of new cases in the U.S. alone,” IceCure president and CEO Hezi Himelfarb said.
IceCure’s system is a minimally invasive procedure that has clear advantages over complicated and expensive surgical solutions for excising tumors, which involve hospital stays, surgery, and prolonged recovery, Himelfarb said. A pre-clinical trial on animals at Kameda Medical Center found it more effective compared with other cryoablation methods.
Lung cancer is the biggest killer of all types of cancer in both men and women, accounting for more deaths than the next three cancers — colon cancer, breast cancer, and prostate cancer — combined.
IceCure started in 2006 and has raised about $20 million in investment funding, including $10 million in an initial public offering on the Tel Aviv Stock Exchange.